We've found
17,797
archived clinical trials in
Peripheral Vascular Disease
We've found
17,797
archived clinical trials in
Peripheral Vascular Disease
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiac SPECT With Rotating Slant Hole Collimator
Updated: 4/4/2018
Myocardial Perfusion SPECT Using a Rotating Multi-segment Slant-hole Collimator
Status: Enrolling
Updated: 4/4/2018
Cardiac SPECT With Rotating Slant Hole Collimator
Updated: 4/4/2018
Myocardial Perfusion SPECT Using a Rotating Multi-segment Slant-hole Collimator
Status: Enrolling
Updated: 4/4/2018
Click here to add this to my saved trials
Cardiac MRI for Patients Enrolled in INFUSE-AMI
Updated: 4/4/2018
Cardiac MRI for Patients Enrolled in INFUSE-AMI
Status: Enrolling
Updated: 4/4/2018
Cardiac MRI for Patients Enrolled in INFUSE-AMI
Updated: 4/4/2018
Cardiac MRI for Patients Enrolled in INFUSE-AMI
Status: Enrolling
Updated: 4/4/2018
Click here to add this to my saved trials
Age-Related Changes in Body Composition
Updated: 4/4/2018
Age-Associated Changes in Regional Adiposity and Novel Cardiovascular Risk Factors
Status: Enrolling
Updated: 4/4/2018
Age-Related Changes in Body Composition
Updated: 4/4/2018
Age-Associated Changes in Regional Adiposity and Novel Cardiovascular Risk Factors
Status: Enrolling
Updated: 4/4/2018
Click here to add this to my saved trials
Age-Related Changes in Body Composition
Updated: 4/4/2018
Age-Associated Changes in Regional Adiposity and Novel Cardiovascular Risk Factors
Status: Enrolling
Updated: 4/4/2018
Age-Related Changes in Body Composition
Updated: 4/4/2018
Age-Associated Changes in Regional Adiposity and Novel Cardiovascular Risk Factors
Status: Enrolling
Updated: 4/4/2018
Click here to add this to my saved trials
Genetics of Hypertension Associated Treatments (GenHAT)
Updated: 4/4/2018
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment
Status: Enrolling
Updated: 4/4/2018
Genetics of Hypertension Associated Treatments (GenHAT)
Updated: 4/4/2018
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment
Status: Enrolling
Updated: 4/4/2018
Click here to add this to my saved trials
Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs)
Updated: 4/5/2018
Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs)
Status: Enrolling
Updated: 4/5/2018
Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs)
Updated: 4/5/2018
Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs)
Status: Enrolling
Updated: 4/5/2018
Click here to add this to my saved trials
Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
Updated: 4/5/2018
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel (EDOX-APT): A Prospective Randomized Study
Status: Enrolling
Updated: 4/5/2018
Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
Updated: 4/5/2018
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel (EDOX-APT): A Prospective Randomized Study
Status: Enrolling
Updated: 4/5/2018
Click here to add this to my saved trials
RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain
Updated: 4/6/2018
RANOLAZINE STUDY: The Effect of Ranolazine on Speckle Tracking Derived Myocardial Strain in Regions of Non-Revascularizable Ischemic Myocardium
Status: Enrolling
Updated: 4/6/2018
RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain
Updated: 4/6/2018
RANOLAZINE STUDY: The Effect of Ranolazine on Speckle Tracking Derived Myocardial Strain in Regions of Non-Revascularizable Ischemic Myocardium
Status: Enrolling
Updated: 4/6/2018
Click here to add this to my saved trials
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Status: Enrolling
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Status: Enrolling
Updated: 4/10/2018
Click here to add this to my saved trials
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Status: Enrolling
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Status: Enrolling
Updated: 4/10/2018
Click here to add this to my saved trials
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Status: Enrolling
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Status: Enrolling
Updated: 4/10/2018
Click here to add this to my saved trials
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Status: Enrolling
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Status: Enrolling
Updated: 4/10/2018
Click here to add this to my saved trials
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Status: Enrolling
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Updated: 4/10/2018
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Status: Enrolling
Updated: 4/10/2018
Click here to add this to my saved trials